SCHEMBL16397212

SCHEMBL16397212

CC(C)(C)OC(=O)Cc1ccccc1OCc1cc(Cl)cc(C#C[Si](C)(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 5/20 0.37
▸ MTNR1B P49286 5/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ PTGER1 P34995 1/20 0.37
▸ TP53 P04637 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ GABRA6 Q16445 1/20 0.34
▸ CFD P00746 6/20 0.34
▸ F11 P03951 6/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16396784 0.87 CFD (0.46) PTGER1CFDF11KLKB1TPSB2
SCHEMBL16396476 0.86 MTNR1A (0.40) MTNR1AMTNR1BCYP2C9PTGER1TP53
SCHEMBL16397128 0.83 PTGER1 (0.37) MTNR1AMTNR1BCYP2C9PTGER1TP53
SCHEMBL16397377 0.81 CFD (0.43) MTNR1AMTNR1BCYP2C9PTGER1TP53
SCHEMBL16410429 0.79 MEN1 (0.43) MTNR1AMTNR1BCYP2C9PTGER1TP53
SCHEMBL16397192 0.78 MTNR1A (0.38) MTNR1AMTNR1BCYP2C9PTGER1TP53
SCHEMBL16396265 0.78 MTNR1A (0.40) MTNR1AMTNR1BCYP2C9PTGER1CFD
SCHEMBL16396881 0.78 MTNR1A (0.40) MTNR1AMTNR1BCYP2C9PTGER1CFD
SCHEMBL16397748 0.77 CFD (0.38) MTNR1AMTNR1BCYP2C9PTGER1TP53
SCHEMBL16396123 0.76 AAK1 (0.40) MTNR1AMTNR1BCYP2C9PTGER1CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB MTNR1A 2124/4885MTNR1B 966/4885CYP2C9 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback